Sociodemographic and clinical profile of patients with Multiple Myeloma treated in Passo Fundo, Rio Grande do Sul
DOI:
https://doi.org/10.33448/rsd-v13i11.47379Keywords:
Multiple Myeloma; Epidemiological profile; Adverse effects.Abstract
Introduction: Multiple Myeloma (MM) is a malignant neoplasm related to the bone marrow. It affects several sites, producing varied and non-specific symptoms that make diagnosis difficult. Most patients are over 60 years old and consequently have comorbidities. Treatment protocols are evolving, but the drugs used still have toxic potential, causing significant adverse effects. The objective was to analyze the sociodemographic and clinical profile of patients diagnosed with MM and the main adverse effects observed after starting treatment. Methodology: A cross-sectional, descriptive, and observational study was carried out with patients with MM treated at a Passo Fundo hospital (RS). Interviews were conducted using a questionnaire and electronic medical records were analyzed. Results: there was a predominance of males, with a median age of 60.4 years and white color. Systemic arterial hypertension and cardiovascular diseases were the predominant comorbidities. The effects of the chemotherapy drugs can compromise quality of life and lead to poor patient compliance, so it is important to know the profile and individualize each therapy. The most used treatment protocol was Bortezomib+Cyclophosphamide+Dexamethasone (VCD). The most common side effects were loss of appetite, weight loss, headache, and neuropathy. Conclusion: This is an increasingly prevalent disease due to the aging population. Knowing more about patients' profiles can facilitate diagnosis, speed up neoplastic control, and allow for better allocation of public health resources.
References
American Cancer Society. (2018). Key Statistics About Multiple Myeloma https://www.cancer.org/cancer/types/multiple-myeloma/about/key-statistics.html
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., & Pandey, D. K. (2023). Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes and Diseases, 10(4), 1367–1401.
Campolina, A. G., Adami, F., Santos, J. L. F., & Lebrão, M. L. (2013). A transição de saúde e as mudanças na expectativa de vida saudável da população idosa: possíveis impactos da prevenção de doenças crônicas. Cadernos de Saude Publica, 29(6), 1217–1229.
Brasil. Ministério da Saúde - Conitec. (2022). Diretrizes Diagnósticas e Terapêuticas do Mieloma Múltiplo. Recuperado em 09 setembro de 2024, de https://www.gov.br/conitec/pt-br/midias/consultas/relatorios/2022/20220526_ddt_mieloma_multiplo_cp.pdf
Brasil. Ministério da Saúde (2019). Painel de Oncologia. http://tabnet.datasus.gov.br/cgi/dhdat.exe?PAINEL_ONCO/PAINEL_ONCOLOGIABR.def
Ferreira, M. L. L., Souza, A. I. de, Ferreira, L. O. C., Moura, J. F. do P., & Junior, J. I. C. (2015). Qualidade de vida relacionada à saúde de idosos em tratamento quimioterápico. Revista Brasileira de Geriatria e Gerontologia, 18(1), 165–177.
Forsgård, R. A., Korpela, R., Holma, R., Lindén, J., Frias, R., Spillmann, T., & Österlund, P. (2016). Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague–Dawley rats. Cancer Chemotherapy and Pharmacology, 78(4), 863–874.
Furini, A. A. da C., Encinas, M., Alves, M. C., Madeira, E. B., Maschio de Lima, T. A., Rodrigues, J. F., & Fazzio, C. S. D. J. (2018). Perfil de pacientes com diagnóstico patológico de mieloma múltiplo em hospital de ensino. Arquivos de Ciências da Saúde, 25(1), 61.
Garcia, C. S., Righes, C. da S., Muller, K. de T. C., Ricas, S. M. M. de C., & Almeida, E. B. de. (2020). Perfil epidemiológico de pacientes diagnosticados com mieloma múltiplo em hospital de referência para neoplasias malignas hematológicas. Revista Brasileira de Análises Clínicas, 52(3), 1–7.
Garnica, M., Crusoe, E. D. Q., Ribeiro, G., Bittencourt, R., Magalhães, R. J. P., Zanella, K. R., Hallack Neto, A. E., Lima, J. S., Solo, C. B., Souza, E. G., Fernandes, A. M., Maiolino, A., & Hungria, V. (2024). COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality –cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM). Hematology, Transfusion and Cell Therapy, 46(2), 153–160.
Guedes, A., Becker, R. G., & Teixeira, L. E. M. (2023). Multiple Myeloma (Part 1) - Update on Epidemiology, Diagnostic Criteria, Systemic Treatment and Prognosis TT - Mieloma múltiplo (Parte 1) - Atualização sobre epidemiología, critérios diagnósticos, tratamento sistêmico e prognóstico. Rev. bras. ortop, 58(3), 361–367.
Herriot, L. B. (2021). Mieloma Múltiplo no Brasil: cenário atual e fatores associados ao prognóstico em uma coorte hospitalar de pacientes com doença extramedular (Tese de Mestrado). Em Fundação Oswaldo Cruz, Escola Nacional de Saúde Pública Sérgio Arouca, Rio de Janeiro (RJ), Brasil. https://www.arca.fiocruz.br/handle/icict/63585
Hungria, V. T. D. M. (2007). Doença óssea em mieloma múltiplo. Revista Brasileira de Hematologia e Hemoterapia, 29(1), 60–66.
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) (Brasil). (2020). Estimativa 2020 : incidência de câncer no Brasil. Recuperado em 09 setembro de 2024, de https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf
Jurczyszyn, A., Hutch, R., Waszczuk-Gajda, A., Suska, A., Krzanowska, K., & Vesole, D. H. (2020). Monoclonal gammopathies of undetermined significance and smoldering myeloma. Acta Haematologica Polonica, 51(4), 193–202.
Kerckhove, N., Collin, A., Condé, S., Chaleteix, C., Pezet, D., Balayssac, D., & Guastella, V. (2018). Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology. Bulletin du Cancer, 105(11), 1020–1032.
Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., Lust, J., McCurdy, A., Russell, S. J., Zeldenrust, S. R., Kyle, R. A., & Rajkumar, S. V. (2014). Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients. Leukemia, 28(5), 1122–1128.
Malek, E., Wang, G.-M., Tatsuoka, C., Cullen, J., Madabhushi, A., & Driscoll, J. J. (2023). Machine Learning Approach for Rapid, Accurate Point-of-Care Prediction of M-Spike Values in Multiple Myeloma. JCO Clinical Cancer Informatics, 7.
Mc, Craik, C., & Adam Moser and Darrin M. York, K. R. (2008). New Drugs and Novel Mechanisms of Action in Multiple Myeloma in 2013: A Report from the International Myeloma Working Group (IMWG). Bone, 23(1), 1–7.
McQuade, R. M., Stojanovska, V., Abalo, R., Bornstein, J. C., & Nurgali, K. (2016). Chemotherapy-induced constipation and diarrhea: Pathophysiology, current and emerging treatments. Frontiers in Pharmacology, 7(NOV), 1–14.
Melton, L. J., Kyle, R. A., Achenbach, S. J., Oberg, A. L., & Rajkumar, S. V. (2005). Fracture risk with multiple myeloma: A population-based study. Journal of Bone and Mineral Research, 20(3), 487–493.
Moraes Hungria, V. T., Martínez-Baños, D. M., Peñafiel, C. R., Miguel, C. E., Vela-Ojeda, J., Remaggi, G., Duarte, F. B., Cao, C., Cugliari, M. S., Santos, T., Machnicki, G., Fernandez, M., Grings, M., Ammann, E. M., Lin, J. H., Chen, Y. W., Wong, Y. N., & Barreyro, P. (2020). Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008–2016. British Journal of Haematology, 188(3), 383–393.
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Medical sciences (Basel, Switzerland), 9(1), 1–14.
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Santa Maria/RS. Ed. UAB/NTE/UFSM.
Pike, C. T., Birnbaum, H. G., Muehlenbein, C. E., Pohl, G. M., & Natale, R. B. (2012). Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung Cancer. Chemotherapy Research and Practice, 2012, 1–10.
Rajkumar, S. V. (2020). Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. American Journal of Hematology, 95(5), 548–567.
Saad, F., Lipton, A., Cook, R., Chen, Y. M., Smith, M., & Coleman, R. (2007). Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer, 110(8), 1860–1867.
Shitsuka, R. et al. (2014). Matemática fundamental para tecnologia. (2ed.). Editora Erica.
Sonmez, M., Akagun, T., Topbas, M., Cobanoglu, U., Sonmez, B., Yilmaz, M., Ovali, E., & Omay, S. B. (2008). Effect of pathologic fractures on survival in multiple myeloma patients: A case control study. Journal of Experimental and Clinical Cancer Research, 27(1), 1–4.
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
Toassi, R. F. C. & Petry, P. C. (2021). Metodologia científica aplicada à área da Saúde. (2ed.). Editora da UFRGS.
Vieira, S. (2021). Introdução à bioestatistica. Ed. GEN/Guanabara Koogan.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Enzo Castro Lima; Mariana Taina Kayser; Mateus Silva Souza; Izabelle Cavanus Fontana; Luiz Eduardo Santi dos Santos; Denise Ramos de Almeida
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
